tiagabine

Tiagabine (NO050328) 是具有抗惊厥特性的选择性 GABA 再摄取抑制剂，在突触体、神经元和神经胶质中，能够抑制 [3H]GABA 的重摄取，IC50值分别为 67、446 和 182 nM。

Tiagabine hydrochloride (NO050328 hydrochloride) 是具有抗惊厥特性的选择性GABA 再摄取抑制剂，在突触体、神经元和神经胶质中，能够抑制 [3H]GABA 的重摄取，IC50值分别为 67、446 和 182 nM。

Tiagabine hydrochloride hydrate 是一种有效、选择性的 GABA uptake 抑制剂；在突触体、神经元和神经胶质中，能够抑制 [3H] GABA 的摄取，他们的 IC50 值分别为 67，446 和 182 nM。Tiagabine hydrochloride hydrate 能够用作抗惊厥剂。

Tiagabine-d6 is intended for use as an internal standard for the quantification of tiagabine by GC- or LC-MS. Tiagabine is an inhibitor of GABA transporter 1. It inhibits seizures induced by DMCM in mice. Tiagabine reduces allodynia in a rodent model of neuropathic pain when used at a dose of 72.8 µmol/kg, and it acts synergistically with gabapentin to delay pain responses in mice in the hot plate test. Formulations containing tiagabine have been used as adjunctive therapies in the treatment of partial seizures.

Apatinib, also known as Rivoceranib and YN-968D1, is an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. The free-base form is also known as Rivoceranib. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.